74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Inspire Medical Systems Inc
Closed
SectorHealthcare
158.24 6.62
Overview
Share price change
24h
Min
147.33
Max
159.66
Income | 17M 35M |
|---|---|
Sales | 37M 240M |
P/E Sector Avg | 82.216 57.333 |
EPS | 1.15 |
Profit margin | 14.694 |
Employees | 1,246 |
EBITDA | 41M 57M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +40.1% upside |
Next Earnings | 5 May 2025 |
|---|
Market Cap | 4.3B |
|---|---|
Previous open | 151.62 |
Previous close | 158.24 |
Inspire Medical Systems Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Inspire Medical Systems Inc Forecast
Price Target
By TipRanks
40.1% upside
12 Months Forecast
Average 221.64 USD 40.1%
High 270 USD
Low 175 USD
Based on 14 Wall Street analysts offering 12 month price targets forInspire Medical Systems Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Inspire Medical Systems Inc
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
